Results 51 to 60 of about 3,573,509 (380)

Norovirus Protease Structure and Antivirals Development

Viruses, 2021
Human norovirus (HuNoV) infection is a global health and economic burden. Currently, there are no licensed HuNoV vaccines or antiviral drugs available.
Boyang Zhao, Liya Hu, Yongcheng Song, Ketki Patil, Sasirekha Ramani, Robert L. Atmar, Mary K. Estes, B. V. Venkataram Prasad   +7 more
doaj   +1 more source

Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24. [PDF]

, 2016
Off-target binding of hydrophobic drugs can lead to unwanted side effects, either through specific or non-specific binding to unintended membrane protein targets.
Carpenter, Elisabeth P, Gault, Joseph, Marcoux, Julien, Mehmood, Shahid, Michaelis, Susan, Quigley, Andrew, Robinson, Carol V, Young, Stephen G   +7 more
core   +2 more sources

Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals

Frontiers in Chemistry, 2022
Considering the significant impact of the recent COVID-19 outbreak, development of broad-spectrum antivirals is a high priority goal to prevent future global pandemics. Antiviral development processes generally emphasize targeting a specific protein from
Khushboo Bafna, Khushboo Bafna, Christopher L. Cioffi, Robert M. Krug, Gaetano T. Montelione, Gaetano T. Montelione   +5 more
doaj   +1 more source

Structure of protease-cleaved escherichia coliα-2-macroglobulin reveals a putative mechanism of conformational activation for protease entrapment [PDF]

, 2015
Bacterial -2-macroglobulins have been suggested to function in defence as broad-spectrum inhibitors of host proteases that breach the outer membrane.
Burchmore, R.J.S., Byron, O., Cogdell, R.J., Fyfe, C.D., Grinter, R., Josts, I., Mosbahi, K., Roszak, A.W., Walker, D., Wall, D.M.   +9 more
core   +2 more sources

Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs

Molecules, 2019
HIV protease inhibitors against the viral protease are often hampered by drug resistance mutations in protease and in the viral substrate Gag. To overcome this drug resistance and inhibit viral maturation, targeting Gag alongside protease rather than ...
Chinh Tran-To Su, Darius Wen-Shuo Koh, Samuel Ken-En Gan   +2 more
doaj   +1 more source

Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease

Microorganisms, 2020
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The viral outbreak started in late 2019 and rapidly became a serious health threat to the global population.
Qingxin Li, C. Kang
semanticscholar   +1 more source

Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System

Viruses, 2015
Retroviral protease inhibitors (PIs) are fundamental pillars in the treatment of HIV infection and acquired immunodeficiency syndrome (AIDS). Currently used PIs are designed against HIV-1, and their effect on HIV-2 is understudied.
Mohamed Mahdi, Zsófia Szojka, János András Mótyán, József Tőzsér   +3 more
doaj   +1 more source

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat

Retrovirology, 2011
Background Maturation inhibitors are an experimental class of antiretrovirals that inhibit Human Immunodeficiency Virus (HIV) particle maturation, the structural rearrangement required to form infectious virus particles.
Konvalinka Jan, Maas Renée EM, Schipper Pauline J, Pokorná Jana, van Maarseveen Noortje M, Fun Axel, Nijhuis Monique   +6 more
doaj   +1 more source

Rapid enzymatic test for phenotypic HIV protease drug resistance [PDF]

, 2003
A phenotypic resistance test based on recombinant expression of the active HIV protease in E. coli from patient blood samples was developed. The protease is purified in a rapid onestep procedure as active enzyme and tested for inhibition by five selected
Assfalg-Machleidt, Irmgard, Helm, K. von der, Hoffmann, D., Koszinowski, U., Machleidt, Werner, Nitschko, H.   +5 more
core   +1 more source

In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. [PDF]

, 2010
BackgroundCruzain, the major cysteine protease of Trypanosoma cruzi, is an essential enzyme for the parasite life cycle and has been validated as a viable target to treat Chagas' disease.
Brinen, Linda S, Chen, Yen Ting, Doyle, Patricia S, Hansell, Elizabeth, Kerr, Iain D, McKerrow, James H, Roush, William R   +6 more
core   +7 more sources